Neutralization tiers of HIV-1.

/in

Montefiori DC, Roederer M, Morris L, Seaman MS. Neutralization tiers of HIV-1. Curr Opin HIV AIDS. 2018 Mar;13(2):128-136.

The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles.

/in

Gabriela M. Webb, Shengbin Li, Gwantwa Mwakalundwa, Joy M. Folkvord, Justin M. Greene, Jason S. Reed, Jeffery J. Stanton, Alfred W. Legasse, Theodore Hobbs, Lauren D. Martin, Byung S. Park, James B. Whitney, Emily K. Jeng, Hing C. Wong, Douglas F. Nixon, R. Brad Jones, Elizabeth Connick, Pamela J. Skinner, Jonah B. Sacha; The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles. Blood Adv 2018; 2 (2): 76–84.

Exploiting glycan topography for computational design of Env glycoprotein antigenicity.

/in

Yu W H, Zhao P, Draghi M, Arevalo C, Karsten CB, Suscovich TJ, Gunn B, Streeck H, Brass AL, Tiemeyer M, Seaman M, Mascola JR, Wells L, Lauffenburger DA, Alter G. Exploiting glycan topography for computational design of Env glycoprotein antigenicity. PLoS Comput Biol. 2018 Apr 20;14(4):e1006093.

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.

/in

Cohen YZ, Lorenzi JCC, Seaman MS, Nogueira L, Schoofs T, Krassnig L, Butler A, Millard K, Fitzsimons T, Daniell X, Dizon JP, Shimeliovich I, Montefiori DC, Caskey M, Nussenzweig MC. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells. J Virol. 2018 Feb 12;92(5).

Therapeutic efficacy of vectored PGT121 gene delivery in HIV-1-infected humanized mice.

/in

Badamchi-Zadeh A, Tartaglia LJ, Abbink P, Bricault CA, Liu PT, Boyd M, Kirilova M, Mercado NB, Nanayakkara OS, Vrbanac VD, Tager AM, Larocca RA, Seaman MS, Barouch DH. Therapeutic efficacy of vectored PGT121 gene delivery in HIV-1-infected humanized mice. J. Virol. 2018; 92:e01925-17.

A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge.

/in

Madani N, Princiotto AM, Mach L, Ding S, Prevost J, Richard J, Hora B, Sutherland L, Zhao CA, Conn BP, Bradley T, Moody MA, Melillo B, Finzi A, Haynes BF, Smith Iii AB, Santra S, Sodroski J. A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. 2018; Nat Commun; 9(1):2363.

Fetal neuropathology in Zika virus-infected pregnant female rhesus monkeys.

/in

Martinot AJ, Abbink P, Afacan O, Prohl AK, Bronson R, Hecht JL, Borducchi EN, Larocca RA, Peterson RL, Rinaldi W, Ferguson M, Didier PJ, Weiss D, Lewis MG, De La Barrera RA, Yang E, Warfield SK, Barouch DH. Fetal neuropathology in Zika virus-infected pregnant female rhesus monkeys. Cell 2018; 173:1111-1122.

Neutralizing antibody responses following long-term vaccination with HIV-1 Env gp140 in guinea pigs.

/in ,

Bricault CA, Kovacs JM, Badamchi-Zadeh A, McKee K, Shields JL, Gunn BM, Neubauer GH, Ghantous F, Jennings J, Gillis L, Perry J, Nkolola JP, Alter G, Chen B, Stephenson KE, Doria-Rose N, Mascola JR, Seaman MS, Barouch DH. Neutralizing antibody responses following long-term vaccination with HIV-1 Env gp140 in guinea pigs. J. Virol. 2018; 92:e00369-18.

Therapeutic vaccination for HIV: hopes and challenges.

/in

Stephenson KE. Therapeutic vaccination for HIV: hopes and challenges. Curr Opin HIV AIDS. 2018 Sep;13(5):408-415. doi: 10.1097/COH.0000000000000491. Review. PubMed PMID: 29957615.

A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.

/in

Gautam R, Nishimura Y, Gaughan N, Gazumyan A, Schoofs T, Buckler-White A, Seaman MS, Swihart BJ, Follmann DA, Nussenzweig MC, Martin MA. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat Med. 2018 May;24(5):610-616.